Last reviewed · How we verify

Insulin NovoRapid versus Actrapid

Odense University Hospital · FDA-approved active Small molecule

NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, while Actrapid is a regular human insulin with a slower onset of action.

NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, while Actrapid is a regular human insulin with a slower onset of action. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameInsulin NovoRapid versus Actrapid
SponsorOdense University Hospital
Drug classInsulin
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Both drugs are insulin formulations used to manage blood glucose in diabetes. NovoRapid (insulin aspart) is a rapid-acting analog with onset within 10-20 minutes, peak effect at 1-3 hours, and duration of 3-5 hours, making it suitable for mealtime coverage. Actrapid (regular human insulin) has a slower onset of 30 minutes to 1 hour, peak at 2-4 hours, and longer duration of 6-8 hours, traditionally used for basal coverage or when rapid action is not required.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: